CLAIMS

1. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating pain in a human being in need thereof, wherein the solid pharmaceutical composition comprises a bicarbonate, a meloxicam, and a sulfobutyl ether β-cyclodextrin (SBEβCD), wherein the meloxicam and the SBEβCD have a molar ratio of about 0.8 to about 1.2, wherein the bicarbonate provides improved dissolution of meloxicam in gastric fluid as compared with a first reference pharmaceutical composition that: 1) contains the same amount of the meloxicam; 2) does not contain a bicarbonate; and 3) does not contain a carbonate, wherein the medicament is formulated for oral administration to the human being, and wherein the solid pharmaceutical composition contains 400 mg to 1000 mg of the bicarbonate.

2. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating pain in a human being in need thereof, wherein the solid pharmaceutical composition comprises a bicarbonate, a meloxicam, and a sulfobutyl ether β-cyclodextrin (SBEβCD), wherein the meloxicam and the SBEβCD have a molar ratio of about 0.8 to about 1.2, wherein the bicarbonate provides improved dissolution of meloxicam in gastric fluid as compared with a second reference pharmaceutical composition that: 1) contains the same amount of the meloxicam; 2) contains an amount of a carbonate that achieves about the same pH as the bicarbonate; and 3) does not contain a bicarbonate, wherein the medicament is formulated for oral administration to the human being, and wherein the solid pharmaceutical composition contains 400 mg to 1000 mg of the bicarbonate.

3. Use according to claim 1 or 2, wherein the solid pharmaceutical composition comprises a pharmaceutically acceptable excipient.

4. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition further comprises an acid inhibitor.

5. Use according to claim 4, wherein the acid inhibitor is esomeprazole.

6. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition is in a tablet form.

7. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition comprises between 1 mg to 50 mg of meloxicam.

8. Use according to claim 7, wherein the solid pharmaceutical composition comprises about 15 mg of meloxicam.

9. Use according to claim 7, wherein the solid pharmaceutical composition comprises about 20 mg of meloxicam.

10. Use according to any one of the preceding claims, wherein the bicarbonate is sodium bicarbonate or potassium bicarbonate.

11. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition comprises 500 mg of sodium bicarbonate.

12. Use according to claim 2, wherein the carbonate in the second reference pharmaceutical composition is potassium carbonate.

13. Use according to any one of claims 5 to 12, wherein between 30 mg to 50 mg of esomeprazole is present in the solid pharmaceutical composition.

14. Use according to any one of the preceding claims, wherein, 120 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam is at least 3 times that of the first or the second reference pharmaceutical composition.

15. Use according to any one of claims 3 to 13, wherein, 120 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam is at least 5 times that of the first or the second reference pharmaceutical composition.

16. Use according to any one of the preceding claims, wherein, 15 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam is at least 10% more than that of the first or the second reference pharmaceutical composition.

17. Use according to any one of claims 3 to 13, wherein, 15 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam is at least 2 times that of the first or the second reference pharmaceutical composition.

18. Use according to any one of the preceding claims, wherein the pain is inflammatory pain.

19. Use according to any one of claims 1 to 17, wherein the solid pharmaceutical composition is to be orally administered to the human being to treat osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis.